BioCentury
ARTICLE | Company News

Celgene licenses GlobeImmune cancer candidate

August 4, 2015 11:36 PM UTC

Celgene Corp. (NASDAQ:CELG) exercised its option to license exclusive, worldwide rights to oncology candidate GI-6207 from GlobeImmune Inc. (NASDAQ:GBIM). The therapy targets cancers that express carcinoembryonic antigen (CEA). GlobeImmune expects results in 2H16 from a Phase II trial to treat medullary thyroid cancer (MTC).

GlobeImmune will receive a $1.9 million option fee and is eligible for undisclosed regulatory and sales milestones, plus royalties. GlobeImmune declined to disclose further financial details; Celgene did not respond to inquiries. ...